Neuronal Protective Effect of Nosustrophine in Cell Culture Models DOI Open Access
Massimo Tusconi

Journal of Exploratory Research in Pharmacology, Journal Year: 2023, Volume and Issue: 8(4), P. 267 - 268

Published: Dec. 14, 2023

The role of nootropic supplements is becoming increasingly relevant in today's integrated therapeutic landscape. 1The choice adjunctive therapy complex because the elaborate nature drugs and, consequently, potentially resulting drug interactions.The use a nootropic, although it has an active component, turns out to be less disruptive overall fewer interactions from its very nature; another aspect not underestimated general propensity patient take product which he or she does attribute exact as generally used therapy, and this allows clinician able administer effective add-on with good compliance on part patient. 2 Among supplements, Nosustrophine important role.The effects supplement are manifold, currently, found treatment Alzheimer's disease (AD).Among pharmacological interventions, most widely AD natural products (25.6%), followed by anti-amyloid beta

Language: Английский

The impact of genetic variability on Alzheimer’s therapies: obstacles for pharmacogenetic progress DOI
Ramón Cacabelos,

Olaia Martínez-Iglesias,

Natalia Cacabelos

et al.

Expert Opinion on Drug Metabolism & Toxicology, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 28

Published: Jan. 21, 2025

Genetic load influences the therapeutic response to conventional drugs in Alzheimer's disease (AD). Pharmacogenetics (PGx) is best option reduce drug-drug interactions and adverse drug reactions patients undergoing polypharmacy regimens. However, there are important limitations that make it difficult incorporate pharmacogenetics into routine clinical practice. This article analyzes pharmacogenetic apparatus made up of pathogenic, mechanistic, metabolic, transporter, pleiotropic genes responsible for efficacy safety pharmacological treatment, impact genetic on outcome multifactorial treatments, practical aspects effective use PGx. Over 120 closely associated with AD. There an accumulation cerebrovascular (CVn) neurodegenerative (ADn) APOE-4 carriers accumulate more deleterious related other CVn ADn genes, develop earlier, at a biological disadvantage compared non-carriers. CYP2D6-PMs worst responders anti-dementia drugs. Some hinder implementation PGx practice, including lack information many drugs, low number screening protocols, educational deficiencies medical community regarding genomic medicine.

Language: Английский

Citations

1
Preventive Role of Cocoa-Enriched Extract Against Neuroinflammation in Mice DOI Creative Commons
Iván Carrera, Lola Corzo,

Olaia Martínez-Iglesias

et al.

Neurology International, Journal Year: 2025, Volume and Issue: 17(4), P. 47 - 47

Published: March 24, 2025

Background: Chronic aberrant inflammation is a crucial step in mediating cerebrovascular and neurodegenerative pathologies, including Alzheimer’s Parkinson’s disease. Due to their exceptional antioxidant properties ability alter imbalance metabolism reactive response, cocoa-derived flavanols are being investigated as potential bioactive substances modulate reverse these inflammation-associated disorders. Objective: The present study will focus on the possible beneficial effects of extract, enhanced with other phytochemicals such spirulina pineapple, selected biomarkers inflammatory, metabolic, processes. Methods: A mice model was treated extract cocktail, biomolecular data obtained by performing immunohistochemical biochemical analysis. Results: Results show that mitigates neuroinflammatory processes triggered (decreased expression macrophage CD11b) prevents escalade subsequent neurodegeneration pathologies. Conclusions: results based hypo-vitaminosis, neuroinflammation, inmunoreactive analysis suggest powerful bioproduct for ameliorating mediate metabolic diseases.

Language: Английский

Citations

0
Therapeutic Options in Alzheimer’s Disease: From Classic Acetylcholinesterase Inhibitors to Multi-Target Drugs with Pleiotropic Activity DOI Creative Commons
Ramón Cacabelos,

Olaia Martínez-Iglesias,

Natalia Cacabelos

et al.

Life, Journal Year: 2024, Volume and Issue: 14(12), P. 1555 - 1555

Published: Nov. 26, 2024

Alzheimer’s disease (AD) is a complex/multifactorial brain disorder involving hundreds of defective genes, epigenetic aberrations, cerebrovascular alterations, and environmental risk factors. The onset the neurodegenerative process triggered decades before first symptoms appear, probably due to combination genomic phenomena. Therefore, primary objective any effective treatment intercept in its presymptomatic phases. Since approval acetylcholinesterase inhibitors (Tacrine, Donepezil, Rivastigmine, Galantamine) Memantine, between 1993 2003, no new drug was approved by FDA until advent immunotherapy with Aducanumab 2021 Lecanemab 2023. Over past decade, more than 10,000 compounds potential action on some pathogenic components AD have been tested. limitations these anti-AD treatments stimulated search for multi-target (MT) drugs. In recent years, 1000 drugs MT function studied models. aim address complex multifactorial nature disease. This approach has offer comprehensive benefits single-target therapies, which may be limited their effectiveness intricate pathology AD. A strategy still unexplored agents. Another option could biotechnological products pleiotropic action, among nosustrophine-like represent an attractive, although not definitive, example.

Language: Английский

Citations

1
Alzheimer’s Disease: Understanding Motor Impairments DOI Creative Commons
Jesús Andrade-Guerrero, Humberto Martínez-Orozco, Marcos M. Villegas-Rojas

et al.

Brain Sciences, Journal Year: 2024, Volume and Issue: 14(11), P. 1054 - 1054

Published: Oct. 24, 2024

Alzheimer's disease (AD), the most prevalent neurodegenerative disorder and leading cause of dementia worldwide, profoundly impacts health quality life. While cognitive impairments-such as memory loss, attention deficits, disorientation-predominate in AD, motor symptoms, though common, remain underexplored. These including gait disturbances, reduced cardiorespiratory fitness, muscle weakness, sarcopenia, impaired balance, are often associated with advanced stages AD contribute to increased mortality. Emerging evidence, however, suggests that symptoms may be present earlier can serve predictive markers for older adults. Despite a limited understanding underlying mechanisms driving these several key pathways have been identified, offering avenues further investigation. This review provides an in-depth analysis discussing its progression, potential mechanisms, therapeutic strategies. Addressing alongside decline enhance patient functionality, improve life, support more comprehensive management

Language: Английский

Citations

0
Neuronal Protective Effect of Nosustrophine in Cell Culture Models DOI Open Access
Massimo Tusconi

Journal of Exploratory Research in Pharmacology, Journal Year: 2023, Volume and Issue: 8(4), P. 267 - 268

Published: Dec. 14, 2023

The role of nootropic supplements is becoming increasingly relevant in today's integrated therapeutic landscape. 1The choice adjunctive therapy complex because the elaborate nature drugs and, consequently, potentially resulting drug interactions.The use a nootropic, although it has an active component, turns out to be less disruptive overall fewer interactions from its very nature; another aspect not underestimated general propensity patient take product which he or she does attribute exact as generally used therapy, and this allows clinician able administer effective add-on with good compliance on part patient. 2 Among supplements, Nosustrophine important role.The effects supplement are manifold, currently, found treatment Alzheimer's disease (AD).Among pharmacological interventions, most widely AD natural products (25.6%), followed by anti-amyloid beta

Language: Английский

Citations

0